Diphenhydramine: Nursing Drug Guide, Anticholinergic Sedation & NCLEX Review
First-generation H1 blocker with strong sedation and anticholinergic effects—the bedside failure mode is not “allergy relief” alone but confusion, urinary retention, falls, and CNS depression when nurses miss duplicate dosing in sleep aids, cold products, and topical forms, or stack it with opioids and benzodiazepines in older adults.
U.S. OTC labeling warns marked drowsiness, that alcohol, sedatives, and tranquilizers increase sedation, and to not use any other product containing diphenhydramine (including skin products). Parenteral labeling cautions that antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients and that overdosage in pediatric patients may cause hallucinations, convulsions, or death. Before every dose, reconcile sleep aids and PM analgesics for hidden diphenhydramine and assess voiding and mental status in older adults.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: hunt for hidden diphenhydramine (PM cold/analgesic combos, sleep aids, topical anti-itch), confirm only one sedating antihistamine is active, and in older adults check alertness, voiding, and orthostatic symptoms. If the patient is confused, has not voided, or cannot stay awake—hold and contact pharmacy/prescriber before giving another dose.
Brand names and formulations
Diphenhydramine hydrochloride (HCl) is a first-generation antihistamine with prominent sedative and anticholinergic effects. Products include oral tablets/capsules/liquids, parenteral injection, and topical anti-itch preparations. This guide focuses on oral and IV/IM routes in current U.S. labeling.
- Oral OTC: Benadryl and generics (commonly 25 mg tablets/capsules)
- Sleep / PM combination products: Many contain diphenhydramine or related sedating antihistamines—reconcile with medication reconciliation
- Combination analgesics: Products pairing acetaminophen with diphenhydramine (e.g., PM formulations) — count both active ingredients toward 24-hour totals
- Injection: 50 mg/mL for IV or deep IM when oral therapy is impractical (Fresenius Kabi and other ANDA labels)
- Related salt: Dimenhydrinate contains diphenhydramine—do not double-dose
- Less sedating alternatives: loratadine and fexofenadine — different sedation and dosing profiles (see also nonsedating options in Related Topics)
Indications
Per U.S. OTC Benadryl labeling and diphenhydramine injection prescribing information:
- OTC oral: Temporary relief of hay fever or upper respiratory allergy symptoms (runny nose, sneezing, itchy/watery eyes, itchy nose/throat) and selected common-cold symptoms (runny nose, sneezing)
- IV/IM (when oral impractical): Allergic reactions to blood/plasma; anaphylaxis as adjunct after acute symptoms controlled with epinephrine and standard measures; uncomplicated immediate-type allergic conditions; motion sickness; parkinsonism in defined situations per injection labeling
- Hospital nursing use: PRN allergy/itch, adjunct in anaphylaxis pathways, and acute extrapyramidal symptoms (EPS) per institutional protocol (e.g., with chlorpromazine)
Diphenhydramine treats symptoms such as hives, pruritus, and nasal congestion from histamine release—it does not replace epinephrine for anaphylaxis.
How it works
Diphenhydramine is an H1-receptor antagonist with anticholinergic (drying) and sedative effects per injection labeling. Antihistamines compete with histamine for receptor sites on effector cells.
Because it crosses the blood–brain barrier more than second-generation agents, nurses should expect marked drowsiness, dry mouth, urinary retention, and confusion in susceptible patients—especially older adults and those on other CNS depressants.
Dosing
Match route, concentration, and 24-hour total to the order and product label. Do not combine oral, topical, and parenteral diphenhydramine without prescriber/pharmacy review.
U.S. OTC oral tablets (25 mg) — Benadryl labeling
| Population | Dose |
|---|---|
| Adults and children 12 years and older | 1 to 2 tablets every 4 to 6 hours; do not take more than 6 times in 24 hours (maximum 150 mg/day if taking two tablets per dose) |
| Children 6 to under 12 years | 1 tablet every 4 to 6 hours; do not take more than 6 times in 24 hours |
| Children under 6 years | Do not use (OTC labeling) |
On a small screen, swipe or scroll sideways to see the full table.
IV/IM injection (50 mg/mL) — prescribing information
OTC labeling: ask a doctor before use if you have emphysema/chronic bronchitis, glaucoma, or trouble urinating due to enlarged prostate.
Pharmacokinetics
- Onset: Injectable form has rapid onset per labeling; oral absorption timing not specified in the reviewed injection label
- Distribution: Widely distributed including the CNS (injection labeling)
- Duration of action: Following an average dose, activity reported approximately 4 to 6 hours in some capsule labeling excerpts; clinical sedation may outlast symptom relief
- Metabolism/elimination: Portion excreted unchanged in urine; remainder hepatically metabolized (injection labeling)
- Detailed pharmacokinetic tables: Not specified in the reviewed prescribing information
Safety check — Before you give
Answer these before the first dose or when reconciling home supply:
- Correct patient, drug, strength (25 mg vs 50 mg), route, and scheduled time
- Hidden diphenhydramine in sleep aids, PM analgesics, cough/cold products, and topical anti-itch — OTC warns not to use with any other diphenhydramine product, even on skin
- Only one sedating antihistamine for the same symptom set unless prescriber documents otherwise
- 24-hour dose count — OTC max 6 doses per 24 hours; parenteral adult max 400 mg/day
- Recent alcohol, opioids, benzodiazepines, or other CNS depressants
- Older adult: baseline cognition, fall risk, last void, orthostatic symptoms
- Glaucoma, asthma/COPD, urinary retention risk, or gastric outlet obstruction per warnings
- Pregnancy or breastfeeding — OTC: ask health professional; parenteral labeling contraindicates nursing mothers
Contraindications
- Neonates and premature infants (injection labeling)
- Nursing mothers — antihistamine therapy contraindicated in injection labeling because of higher risk to infants
- Hypersensitivity to diphenhydramine or similar antihistamine chemical structure
- Do not use as a local anesthetic — risk of local necrosis (injection labeling)
- OTC: Do not use to make a child sleepy; do not use with any other product containing diphenhydramine (including skin products)
Use with considerable caution in narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction (injection warnings).
Drug interactions
| Agent | Effect | Nursing action |
|---|---|---|
| Alcohol | Additive sedation per OTC and injection labeling | Counsel to avoid alcohol; assess alertness before discharge or driving |
| CNS depressants (opioids, benzodiazepines, sedative-hypnotics) | Additive CNS depression | Screen MAR and home list; hold if excessive sedation |
| MAO inhibitors | Prolong and intensify anticholinergic (drying) effects | Flag new MAOI therapy for pharmacist review |
| Other antihistamines / hidden diphenhydramine | Duplicate therapy — additive sedation and anticholinergic toxicity | Reconcile PM products and topical forms; clarify single agent with pharmacy |
| Other anticholinergics | Additive dry mouth, confusion, retention, constipation | Review anticholinergic burden in older adults |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral
- May take every 4 to 6 hours per OTC directions; verify 24-hour dose count
- Use calibrated device for liquids; confirm mg per 5 mL on each product
- Do not use OTC oral products in children under 6 years per Benadryl labeling
IV/IM
- For IV or deep IM only — product is not for subcutaneous or intradermal use; local necrosis reported with improper injection routes
- Inspect solution for particulate matter and discoloration before administration
- IV: administer at a rate generally not exceeding 25 mg/min per injection labeling
- Document exact mg, route, and time; high-potency 50 mg/mL vials require double-check per institutional policy
Subcutaneous or intradermal injection; exceeding 25 mg/min IV rate; giving hospital dose while patient also uses home PM sleep product; using diphenhydramine to sedate pediatric patients (OTC warns do not use to make a child sleepy).
Expected therapeutic response
- Reduced sneezing, rhinorrhea, pruritus, and urticaria within hours
- Decreased motion sickness symptoms when used for that indication
- Relief of mild parkinsonism or EPS when ordered for those uses — monitor for excessive sedation
- If symptoms persist despite maximum labeled oral dosing, contact prescriber rather than adding another sedating antihistamine
Red flags — Stop and act
- Anaphylaxis or serious allergic reaction — urticaria with angioedema, bronchospasm, hypotension; injection labeling lists anaphylactic shock as adverse reaction; stop drug and treat per emergency pathway
- Acute confusion, inability to arouse, or new altered mental status — especially in older adults
- Urinary retention, suprapubic discomfort, or no void for unusually long period
- Paradoxical agitation or excitation in children per labeling warnings
- Seizures or hallucinations — overdose risk in pediatric patients per warnings
- Significant hypotension, tachycardia, or near-syncope after dose
Adverse effects
Most frequent adverse reactions are underscored in injection labeling. Nursing priorities are sedation, anticholinergic toxicity, and CNS depression with co-medications.
| Adverse effect | Nursing notes |
|---|---|
| Sedation, sleepiness, fatigue | OTC: marked drowsiness may occur; assess driving and machinery safety |
| Dizziness, disturbed coordination | Higher risk in elderly per warnings |
| Dry mouth, thickened secretions | Anticholinergic effect — hydration and oral care |
| Urinary frequency, difficult urination, urinary retention | Monitor voiding; bladder scan if retention suspected |
| Confusion, restlessness, excitation (children) | Paradoxical reactions possible per labeling |
| Hypotension, headache, palpitations | Check orthostatics in older adults |
| Constipation, nausea, vomiting | Anticholinergic GI effects |
| Blurred vision, diplopia | Assess fall risk; caution in patients with narrow-angle glaucoma per warnings |
On a small screen, swipe or scroll sideways to see the full table.
Serious reports include anaphylactic shock, hemolytic anemia, agranulocytosis, and convulsions per injection labeling.
Overdose, toxicity, and antidote
Antihistamine overdosage may vary from CNS depression to stimulation; stimulation is particularly likely in pediatric patients per injection labeling. Atropine-like signs may occur: dry mouth, fixed dilated pupils, flushing, GI symptoms.
Antidote
No specific antidote is listed in the reviewed prescribing information. Management is symptomatic and supportive.
- Stimulants should not be used (injection overdosage section)
- Vasopressors may be used to treat hypotension
- Secure all formulations — pediatric overdosage may cause hallucinations, convulsions, or death per warnings
Contact local poison control or medical toxicology for intentional overdose, seizures, or severe altered mental status per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Diphenhydramine vs dimenhydrinate — related chemistry; verify active ingredient
- Benadryl vs Benadryl-D or multi-symptom cold products — may contain additional actives
- 25 mg vs 50 mg tablets/capsules and 50 mg/mL injection — high-risk strength confusion
- Oral vs topical — OTC prohibits concurrent diphenhydramine skin products
- PM analgesic + scheduled antihistamine — hidden duplicate dose
- Diphenhydramine vs hydroxyzine or promethazine — all sedating; do not stack without review
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Sleep aid misuse | Many patients do not know PM products contain diphenhydramine—ask to read active ingredients aloud |
| Older adults | Start low, go slow; reassess cognition and gait each shift |
| Night shift / driving | OTC warns careful driving or machinery; document counseling |
| IV push | Never exceed 25 mg/min; never give SC/ID |
| Ask pharmacy when | Duplicate therapy, delirium, retention, or transition from IV to home OTC |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults (~60+) | More likely dizziness, sedation, hypotension; high anticholinergic burden and fall risk |
| Pediatrics | OTC: do not use under 6 years; paradoxical excitation possible; overdose may cause hallucinations, convulsions, or death |
| Neonates / premature infants | Contraindicated (injection labeling) |
| Glaucoma / urinary obstruction | Use considerable caution; ask doctor before OTC use |
| Asthma / lower respiratory disease | Use caution; thickened bronchial secretions per adverse reactions |
| Pregnancy | Category B in animal studies; adequate human studies lacking — use only if clearly needed per injection labeling; OTC: ask health professional |
| Lactation | Parenteral: contraindicated in nursing mothers; LactMed: small occasional doses often acceptable — monitor infant sedation; nonsedating agents preferred |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Level of sedation, orientation, and safe ability to ambulate
- Voiding pattern, bladder distension, and urinary retention symptoms
- Vital signs — orthostatic blood pressure and heart rate in older adults
- Allergy symptom response versus new drug reaction
- Paradoxical agitation or excitation in children
- Respiratory status in patients with asthma or COPD
Document
- Dose, route, concentration, rate (IV), time, and 24-hour cumulative total
- Home OTC reconciliation including PM products and topical forms
- Sedation scale and anticholinergic assessment in older adults
- Prescriber/pharmacy notification when hold criteria met
Patient teaching
- Marked drowsiness can occur — avoid driving or hazardous tasks if sleepy; avoid alcohol and sedating medicines unless approved
- Do not use any other product containing diphenhydramine, including creams and sleep aids, without checking with the care team
- Read active ingredients on cold, allergy, and PM pain products
- Seek urgent care for throat swelling, trouble breathing, or widespread rash
- Report inability to urinate, severe confusion, or persistent dizziness
- Keep all forms out of reach of children — overdose is dangerous
- Pregnant or breastfeeding — ask prescriber before OTC use
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to diphenhydramine or similar antihistamines
- Marked sedation, confusion, or inability to stay awake — especially with opioids, benzodiazepines, or alcohol
- Duplicate diphenhydramine therapy (MAR + home PM product + topical anti-itch)
- Dose exceeds order or labeled maximum (OTC: more than 6 doses/24 h; parenteral adult >400 mg/day)
- Urinary retention or inability to void with bladder discomfort
- Neonate, premature infant, or breastfeeding patient when parenteral labeling contraindication applies
- Patient must perform alertness-dependent work imminently and is already sedated
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
The highest-stakes nursing problems with diphenhydramine are anticholinergic delirium and sedation in older adults, hidden duplicate dosing in OTC sleep/PM products, and CNS stacking with opioids and benzodiazepines.
1. Check-before-you-give protocol
- Right patient, strength, route, time, and 24-hour total from all sources
- One sedating antihistamine for the same indication unless documented otherwise
- Screen home OTC bottles and PM analgesics for diphenhydramine
- Assess mental status, voiding, and orthostatic tolerance in adults 65+
2. High-alert and safety badge
Not a universal high-alert drug on all lists — treat anticholinergic sedation, duplicate OTC dosing, and IV route/concentration errors as the primary safety story3. Clinical workflow: hold and question rules
- If new confusion appears after an evening dose with PM home product on the list, hold and reconcile before the next dose
- If patient has not voided and has suprapubic discomfort, hold and assess retention
- If systemic allergic signs develop, stop diphenhydramine and manage per emergency protocol—not as sole therapy for anaphylaxis
4. Critical teach-back questions
- “What other medicines or creams contain diphenhydramine that you should avoid?” (Any PM sleep/cold product or anti-itch cream with the same active ingredient.)
- “What will you do if you become too sleepy to walk safely?” (Stop dosing, call the team, avoid driving.)
5. Care coordination
Pharmacist: Duplicate therapy review, anticholinergic burden, IV rate and concentration checks
Prescriber: Notify for retention, delirium, paradoxical agitation, or inadequate allergy control at maximum labeled dose
🧠 Quick mental checklist
- Any other diphenhydramine on MAR, skin, or home OTC (PM products, sleep aids)?
- Opioids, benzodiazepines, or alcohol today—will sedation stack?
- Older adult: new confusion, dry mouth, or urinary retention?
- 24-hour total dose within OTC or prescriber maximum?
- IV/IM: giving IV/IM only—not subcutaneous or intradermal?
Diphenhydramine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for diphenhydramine using a tabbed case (MAR, vitals, history, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise cues → analyse anticholinergic burden → prioritise → act → evaluate outcomes (sedation, duplicate hidden dosing, urinary retention).
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Diphenhydramine 25 mg PO q6h PRN itch — 1800 and 0000 given
- Diphenhydramine 50 mg PO at bedtime — scheduled 2100
- Oxycodone 5 mg PO q4h PRN pain — 1700 and 2100 given
- Lorazepam 0.5 mg PO q6h PRN anxiety — 2000 given
- Home med list: patient uses OTC Tylenol PM at night (contains diphenhydramine)
- Sodium 138 mmol/L, potassium 4.0 mmol/L
- BUN 28 mg/dL (baseline 18), creatinine 1.3 mg/dL (stable)
- No new leukocytosis
- 0200: BP 98/54 lying → 86/48 standing; HR 102; RR 18; SpO2 96% on room air
- 2100 (pre-bedtime dose): BP 112/62, HR 88, patient drowsy but arousable
- Temp 36.8 °C
- 78-year-old admitted for cellulitis; baseline A&O ×3 yesterday
- 0130: New confusion, picking at linens, dry mucous membranes
- 0145: Has not voided in 9 h; bladder scan ordered
- 0150: Daughter reports mother “always takes Tylenol PM” at home for sleep
Answer key & rationale
Frequently asked questions
Why is diphenhydramine high risk in older adults?
Labeling warns elderly patients are more likely to experience dizziness, sedation, and hypotension. Anticholinergic effects drive confusion, retention, and fall risk—especially with other sedatives.
When should a nurse hold diphenhydramine?
Hold for hypersensitivity, marked sedation or confusion, duplicate hidden dosing, exceeding maximum daily dose, urinary retention, use in neonates/premature infants per labeling, or alertness-dependent work when sedated.
What is the maximum oral dose for adults?
OTC labeling: 1–2 tablets (25–50 mg) every 4–6 h, not more than 6 times in 24 h. Parenteral max 400 mg/day for adults when oral is impractical.
What adverse effects matter most?
Sedation, dizziness, dry mouth, urinary retention, confusion, hypotension, and paradoxical excitation in children. Duplicate dosing and CNS stacking are common nursing errors.
Is there an antidote for overdose?
No specific antidote per labeling. Supportive care; stimulants should not be used; vasopressors may treat hypotension. Contact local poison control or toxicology per protocol.
What should lactating patients know?
Parenteral labeling contraindicates use in nursing mothers. LactMed supports small occasional doses with infant monitoring; nonsedating antihistamines are preferred for regular use.
References
-
U.S. National Library of Medicine. Benadryl (diphenhydramine hydrochloride) tablet — OTC drug facts. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=702f9786-7ce9-43e4-921d-e1db09612127
-
U.S. National Library of Medicine. Diphenhydramine hydrochloride injection, USP — Prescribing information. DailyMed (Fresenius Kabi USA, LLC).https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc574e74-1fdc-4a61-a1ed-492ae43faed2&type=display
-
Drugs and Lactation Database (LactMed). Diphenhydramine. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501878/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.